Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. (Nasdaq: IMNM) is a clinical-stage targeted oncology company whose news flow is closely tied to the progress of its cancer drug pipeline and capital markets activity. Press releases and updates frequently describe advances in its lead programs, including varegacestat, an investigational oral gamma secretase inhibitor for desmoid tumors, and IM-1021, a ROR1-targeted antibody-drug conjugate (ADC) that uses the company’s proprietary HC74 TOP1 inhibitor payload.
Investors following IMNM news can expect detailed announcements on clinical trial milestones, such as topline data from the global Phase 3 RINGSIDE trial of varegacestat, which met its primary and key secondary endpoints in patients with progressing desmoid tumors. Immunome also issues updates on early clinical activity for IM-1021 in B-cell lymphoma, IND clearance for the FAP-targeted radioligand IM-3050, and progress across its preclinical ADC programs IM-1617, IM-1335 and IM-1340.
In addition to R&D updates, Immunome regularly reports financial and corporate developments. Recent news includes quarterly financial results, guidance on cash runway, and details of a follow-on public offering of common stock under an effective shelf registration statement. The company also discloses inducement stock option grants under its 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), as well as participation in major healthcare and investor conferences.
This IMNM news page aggregates these disclosures so readers can track trial readouts, regulatory plans such as the intended NDA submission for varegacestat, financing transactions, and corporate presentations in one place. For investors, analysts and healthcare professionals, the stream of Immunome news provides insight into the evolution of its targeted oncology pipeline and its use of capital to support ongoing development.
Immunome, Inc. (Nasdaq: IMNM) made progress in its antibody development, notably with IMM-BCP-01, targeting SARS-CoV-2 variants Lambda and Delta Plus. The company plans to submit an IND for IMM-BCP-01 this quarter, alongside anticipated topline data in H1 2022. Financially, for Q3 2021, R&D expenses reached $4.5M, while G&A expenses were $3.2M, leading to a net loss of $7.7M. As of September 30, 2021, cash reserves stood at $56.3M, indicating sufficient resources for ongoing projects.
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company specializing in first-in-class antibody therapeutics, announced that its President and CEO, Purnanand Sarma, Ph.D., will present at the Stifel Healthcare Conference on November 15, 2021, at 8:00 a.m. ET. Interested listeners can access the live audio webcast via the Investor Relations section of Immunome's website, with a replay available for 30 days post-event. Immunome focuses on developing therapies for oncology and infectious diseases, including COVID-19, leveraging its proprietary human memory B cell platform.
Immunome (Nasdaq: IMNM) has submitted a preprint manuscript detailing the preclinical efficacy of its SARS-CoV-2 antibody cocktail, IMM-BCP-01. This cocktail includes three monoclonal antibodies targeting regions of the spike protein, showing significant viral load reduction in infected hamsters. In tests, IMM-BCP-01 demonstrated a potent reduction of live viral titers by approximately 3.2 - 4 logs. This research indicates broad protective capabilities against multiple variants, supporting the potential for non-intravenous delivery in humans.
Immunome, Inc. (Nasdaq: IMNM) presented findings on its anti-interleukin-38 monoclonal antibody program at the 2021 AACR-NCI-EORTC International Conference. The presentation revealed that the antibody effectively binds to IL-38, preventing its interaction with receptors and enhancing myeloid cell activity in vitro. In murine tumor models, the antibody significantly inhibited tumor growth. This data suggests that blocking IL-38 could potentially reverse immune suppression in tumors, providing a promising avenue for cancer treatment.
Immunome, Inc. (NASDAQ: IMNM) announced an oral poster presentation of its anti IL-38 antibody program at the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 7-10, 2021. The presentation, titled “IMM20324, a first-in-class, anti-interleukin-38 monoclonal antibody,” will cover the antibody's effectiveness in inducing robust anti-tumor responses in vivo. This marks a significant milestone for Immunome as it advances its therapeutic programs targeting oncology and infectious diseases, including COVID-19.
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company focused on antibody therapeutics, announced that President and CEO Purnanand Sarma, Ph.D., will present at the Cantor Global Healthcare Conference on September 29, 2021, at 8:40 a.m. ET. Interested parties can access the live audio webcast through the company's Investor Relations page. Immunome leverages its human memory B cell platform to develop first-in-class therapeutics targeting oncology and infectious diseases, including COVID-19.
Immunome, Inc. (Nasdaq: IMNM) announced that its President and CEO, Purnanand Sarma, will present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 21, 2021, at 9:55 a.m. ET. The live audio webcast can be accessed from the Investor Relations section of the company's website and will be available for replay for 30 days following the event. Immunome is focused on developing first-in-class antibody therapeutics, targeting oncology and infectious diseases, including COVID-19.
Immunome, Inc. (Nasdaq: IMNM) announced that its antibody cocktail, IMM-BCP-01, showed strong neutralizing activity against the Lambda and Delta variants of SARS-CoV-2 in pre-clinical studies. The cocktail targets non-overlapping regions of the spike protein, proving effective against multiple strains. Funded by the U.S. Department of Defense, this promising therapeutic aims to combat COVID-19 variants. CEO Purnanand Sarma emphasized the ongoing support from pre-clinical data, reinforcing the importance of IMM-BCP-01 in fighting emerging variants.
Immunome, Inc. (Nasdaq: IMNM) reported robust progress in Q2 2021, particularly in developing IMM-BCP-01, an antibody cocktail targeting SARS-CoV-2. The company secured increased funding from the Department of Defense and demonstrated strong neutralization activity against the Delta variant in preclinical tests. An IND filing for IMM-BCP-01 is planned for Q3 2021, with additional plans for an IL-38 immuno-oncology IND filing in Q4 2021. Financially, R&D expenses were $3.2 million, and the net loss totaled $5.2 million, with cash reserves at $59.8 million.
Immunome (Nasdaq: IMNM) announced promising results for its three-antibody cocktail, IMM-BCP-01, which showed potent neutralizing activity against the SARS-CoV-2 Delta variant in pre-clinical tests. The company received a $17.6 million award from the U.S. Department of Defense to support its COVID program. With concerns over potential COVID-19 resurging due to new variants, Immunome plans to expedite the development of IMM-BCP-01 and submit an IND application to the FDA this quarter, potentially positioning the drug as a long-term solution to COVID-19.